Molecular evidence of engraftment in bone marrow after nonmyeloablative allogeneic stem cell transplant (NMASCT) is an unreliable indicator of residual/recurrent disease in the marrow.
Publication
, Journal Article
Lagoo, AS; Gong, JZ; Rizzieri, DA; Stenzel, TT; Chao, NJ; Buckley, PJ
Published in: BLOOD
November 16, 2001
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2001
Volume
98
Issue
11
Start / End Page
185A / 185A
Publisher
AMER SOC HEMATOLOGY
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Lagoo, A. S., Gong, J. Z., Rizzieri, D. A., Stenzel, T. T., Chao, N. J., & Buckley, P. J. (2001). Molecular evidence of engraftment in bone marrow after nonmyeloablative allogeneic stem cell transplant (NMASCT) is an unreliable indicator of residual/recurrent disease in the marrow. BLOOD, 98(11), 185A-185A.
Lagoo, A. S., J. Z. Gong, D. A. Rizzieri, T. T. Stenzel, N. J. Chao, and P. J. Buckley. “Molecular evidence of engraftment in bone marrow after nonmyeloablative allogeneic stem cell transplant (NMASCT) is an unreliable indicator of residual/recurrent disease in the marrow.” BLOOD 98, no. 11 (November 16, 2001): 185A-185A.
Lagoo AS, Gong JZ, Rizzieri DA, Stenzel TT, Chao NJ, Buckley PJ. Molecular evidence of engraftment in bone marrow after nonmyeloablative allogeneic stem cell transplant (NMASCT) is an unreliable indicator of residual/recurrent disease in the marrow. BLOOD. 2001 Nov 16;98(11):185A-185A.
Lagoo, A. S., et al. “Molecular evidence of engraftment in bone marrow after nonmyeloablative allogeneic stem cell transplant (NMASCT) is an unreliable indicator of residual/recurrent disease in the marrow.” BLOOD, vol. 98, no. 11, AMER SOC HEMATOLOGY, Nov. 2001, pp. 185A-185A.
Lagoo AS, Gong JZ, Rizzieri DA, Stenzel TT, Chao NJ, Buckley PJ. Molecular evidence of engraftment in bone marrow after nonmyeloablative allogeneic stem cell transplant (NMASCT) is an unreliable indicator of residual/recurrent disease in the marrow. BLOOD. AMER SOC HEMATOLOGY; 2001 Nov 16;98(11):185A-185A.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2001
Volume
98
Issue
11
Start / End Page
185A / 185A
Publisher
AMER SOC HEMATOLOGY
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology